SCHEMBL1609082

SCHEMBL1609082

Cc1cccc(Cn2ccc3ccc(C(=O)NO)nc32)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.42
MAPT P10636 7/20 0.41
HDAC8 Q9BY41 4/20 0.41
HDAC6 Q9UBN7 4/20 0.41
HDAC1 Q13547 3/20 0.41
HDAC2 Q92769 3/20 0.41
HDAC3 O15379 2/20 0.41
TP53 P04637 2/20 0.41
POLB P06746 1/20 0.41
LMNA P02545 1/20 0.41
MMP13 P45452 1/20 0.40
HDAC10 Q969S8 2/20 0.39
HDAC9 Q9UKV0 2/20 0.39
HDAC4 P56524 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
NCOR2 Q9Y618 1/20 0.39
PTGER3 P43115 1/20 0.39
DRD4 P21917 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1608723 0.86 MAOB (0.48) HDAC8HDAC6HDAC1HDAC2HDAC3
SCHEMBL1608635 0.86 HDAC6 (0.47) RXFP1MAPTHDAC8HDAC6HDAC1
SCHEMBL1608418 0.85 HDAC6 (0.52) MAPTHDAC8HDAC6HDAC1HDAC2
SCHEMBL1609074 0.85 HDAC6 (0.52) RXFP1MAPTHDAC8HDAC6HDAC1
SCHEMBL1607602 0.85 HDAC6 (0.50) HDAC8HDAC6HDAC1HDAC2HDAC3
SCHEMBL1608085 0.84 ADRA1D (0.41) HDAC8HDAC6HDAC1HDAC2HDAC3
SCHEMBL1608449 0.80 HDAC6 (0.47) HDAC8HDAC6HDAC1HDAC2HDAC3
SCHEMBL1608525 0.80 HDAC6 (0.48) HDAC8HDAC6HDAC1HDAC2HDAC3
SCHEMBL1608516 0.80 HDAC8 (0.44) RXFP1MAPTHDAC8HDAC6HDAC1
SCHEMBL1608716 0.79 HDAC6 (0.44) HDAC8HDAC6HDAC1HDAC2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150320758-A1 SELECTIVE INHIBITORS OF HISTONE DEACTYLASE PHARMACYCLICS LLC 2015-11-12 US disclosed
US-8906954-B2 Selective inhibitors of histone deacetylase PHARMACYCLICS, INC. (US) 2014-12-09 US disclosed
US-20140004174-A1 SELECTIVE INHIBITORS OF HISTONE DEACETYLASE PHARMACYCLICS, INC. (US) 2014-01-02 US disclosed
US-8466193-B2 Selective inhibitors of histone deacetylase PHARMACYCLICS, INC. (US) 2013-06-18 US disclosed
US-20110081409-A1 SELECTIVE INHIBITORS OF HISTONE DEACETYLASE PHARMACYCLICS LLC 2011-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110081409-A1 SELECTIVE INHIBITORS OF HISTONE DEACETYLASE HDAC8, HDAC1, HDAC11 RXFP1 4368/4885MAPT 1413/4885HDAC8 1/4885
US-20150320758-A1 SELECTIVE INHIBITORS OF HISTONE DEACTYLASE HDAC8, HDAC1, HDAC5 RXFP1 4282/4885MAPT 1549/4885HDAC8 1/4885
US-20140004174-A1 SELECTIVE INHIBITORS OF HISTONE DEACETYLASE HDAC8, HDAC1, HDAC11 RXFP1 4368/4885MAPT 1413/4885HDAC8 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.